Cargando…

RAD1901: a novel, orally bioavailable selective estrogen receptor degrader that demonstrates antitumor activity in breast cancer xenograft models

Agents that inhibit estrogen production, such as aromatase inhibitors or those that directly block estrogen receptor (ER) activity, such as selective estrogen receptor modulators and selective estrogen receptor degraders, are routinely used in the treatment of ER-positive breast cancers. However, al...

Descripción completa

Detalles Bibliográficos
Autores principales:	Garner, Fiona, Shomali, Maysoun, Paquin, Dotty, Lyttle, C. Richard, Hattersley, Gary
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2015
Materias:	Preclinical Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4560273/ https://www.ncbi.nlm.nih.gov/pubmed/26164151 http://dx.doi.org/10.1097/CAD.0000000000000271

Ejemplares similares

Pharmacokinetic and pharmacodynamic analysis of fulvestrant in preclinical models of breast cancer to assess the importance of its estrogen receptor-α degrader activity in antitumor efficacy
por: Wardell, Suzanne E., et al.
Publicado: (2019)

LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models
por: Yan, S. Betty, et al.
Publicado: (2012)

Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer
por: Bardia, Aditya, et al.
Publicado: (2021)

Paclitaxel in self-micro emulsifying formulations: oral bioavailability study in mice
por: Oostendorp, Roos L., et al.
Publicado: (2010)

Rad GTPase Deletion Attenuates Post-Ischemic Cardiac Dysfunction and Remodeling
por: Manning, Janet R., et al.
Publicado: (2018)

Estrogen receptor splice variants as a potential source of false-positive estrogen receptor status in breast cancer diagnostics
por: Groenendijk, Floris H., et al.
Publicado: (2013)

Investigating the role of endogenous estrogens, hormone replacement therapy, and blockade of estrogen receptor-α activity on breast metabolic signaling
por: Arnone, Alana A., et al.
Publicado: (2021)

G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer
por: Andreano, Kaitlyn J., et al.
Publicado: (2020)

In Pursuit of Understanding the Role of Estrogens in Regulating Cardiac Structure and Function
por: Villarreal, Francisco
Publicado: (2020)

Targeting ataxia telangiectasia-mutated- and Rad3-related kinase (ATR) in PTEN-deficient breast cancers for personalized therapy
por: Al-Subhi, Nouf, et al.
Publicado: (2018)

Surveillance of spontaneous breast cancer metastasis by TRAIL-expressing CD34(+) cells in a xenograft model
por: Rossini, Anna, et al.
Publicado: (2012)

The Effect of Estrogen on Intracellular Ca(2+) and Na(+) Regulation in Heart Failure
por: Firth, Jahn M., et al.
Publicado: (2020)

Cardiosphere-Derived Cells Demonstrate Metabolic Flexibility That Is Influenced by Adhesion Status
por: Afzal, Junaid, et al.
Publicado: (2017)

Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer
por: Bostner, Josefine, et al.
Publicado: (2017)

Activation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit
por: Bostner, Josefine, et al.
Publicado: (2012)

Clinicopathological significance of ataxia telangiectasia-mutated (ATM) kinase and ataxia telangiectasia-mutated and Rad3-related (ATR) kinase in MYC overexpressed breast cancers
por: Savva, Constantinos, et al.
Publicado: (2019)

Antitumor activity of a rhenium (I)-diselenoether complex in experimental models of human breast cancer
por: Collery, Philippe, et al.
Publicado: (2015)

Antitumor activity of recombinant RGD-IFN-α2a-core fusion protein in vitro
por: Wen, Zhengwei, et al.
Publicado: (2017)

Antitumor and immunomodulatory effects of a novel multitarget inhibitor, CS2164, in mouse hepatocellular carcinoma models
por: Zhou, You, et al.
Publicado: (2019)

Molecular features of androgen-receptor low, estrogen receptor-negative breast cancers in the Carolina breast cancer study
por: Jinna, Nikita D., et al.
Publicado: (2023)

Quality assessment of estrogen receptor and progesterone receptor testing in breast cancer using a tissue microarray-based approach
por: Dekker, T. J. A., et al.
Publicado: (2015)

Estrogen Receptor-α Non-Nuclear Signaling Confers Cardioprotection and Is Essential to cGMP-PDE5 Inhibition Efficacy
por: Fukuma, Nobuaki, et al.
Publicado: (2020)

SLC1A5 co-expression with TALDO1 associates with endocrine therapy failure in estrogen receptor-positive breast cancer
por: Alfarsi, Lutfi H., et al.
Publicado: (2021)

Advanced glycation end products are elevated in estrogen receptor-positive breast cancer patients, alter response to therapy, and can be targeted by lifestyle intervention
por: Walter, Katherine R., et al.
Publicado: (2018)

A prospective cohort study of clinical characteristics and outcomes in Chinese patients with estrogen receptor-negative/progesterone receptor-positive early breast cancer
por: Fan, Yu, et al.
Publicado: (2023)

Six Weeks of Daily Abaloparatide Treatment Increased Vertebral and Femoral Bone Mineral Density, Microarchitecture and Strength in Ovariectomized Osteopenic Rats
por: Bahar, Hila, et al.
Publicado: (2016)

Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models
por: Bergman, Andries M., et al.
Publicado: (2010)

Quantitative proteomic analysis reveals that Luks-PV exerts antitumor activity by regulating the key proteins and metabolic pathways in HepG2 cells
por: Zhao, Chang-Cheng, et al.
Publicado: (2020)

Tie2-Cre–Induced Inactivation of Non-Nuclear Estrogen Receptor-α Signaling Abrogates Estrogen Protection Against Vascular Injury
por: Liu, Pang-Yen, et al.
Publicado: (2022)

The estrogen receptor coactivator AIB1 is a new putative prognostic biomarker in ER-positive/HER2-negative invasive lobular carcinoma of the breast
por: Narbe, Ulrik, et al.
Publicado: (2019)

Improved in vivo antitumor effect of a daunorubicin - GnRH-III bioconjugate modified by apoptosis inducing agent butyric acid on colorectal carcinoma bearing mice
por: Kapuvári, Bence, et al.
Publicado: (2016)

Antitumor activity of the PI3K δ-sparing inhibitor MEN1611 in PIK3CA mutated, trastuzumab-resistant HER2 + breast cancer
por: Fiascarelli, Alessio, et al.
Publicado: (2023)

Where in 1901?
Publicado: (1900)

The Chemists' Exhibition, 1901
Publicado: (1901)

Atlantic City in 1901
Publicado: (1900)

Atlantic City in 1901
Publicado: (1900)

Atlantic City, 1901
Publicado: (1901)

Our 1901 Meeting
Publicado: (1901)

The Graduating Classes of 1901
Publicado: (1901)

Report on Sanitation, Dispensaries and Jails in Rajputana for 1901, and on Vaccination for the Year 1901-1902
Publicado: (1903)

Cannot write session to /tmp/vufind_sessions/sess_2rhk45pp05bh7elepfqqaaroc9